{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,10,31]],"date-time":"2026-10-31T05:31:15Z","timestamp":1793424675751,"version":"4.5.0"},"reference-count":70,"publisher":"Springer Science and Business Media LLC","issue":"1","license":[{"start":{"date-parts":[[2009,3,1]],"date-time":"2009-03-01T00:00:00Z","timestamp":1235865600000},"content-version":"tdm","delay-in-days":0,"URL":"http:\/\/creativecommons.org\/licenses\/by-nc\/2.0"}],"content-domain":{"domain":[],"crossmark-restriction":false},"short-container-title":["Curr Rev Musculoskelet Med"],"published-print":{"date-parts":[[2009,3]]},"DOI":"10.1007\/s12178-009-9046-7","type":"journal-article","created":{"date-parts":[[2009,3,9]],"date-time":"2009-03-09T07:52:56Z","timestamp":1236585176000},"page":"56-64","source":"Crossref","is-referenced-by-count":171,"title":["RANK, RANKL and osteoprotegerin in bone biology and disease"],"prefix":"10.1007","volume":"2","author":[{"given":"H. L.","family":"Wright","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"H. S.","family":"McCarthy","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"J.","family":"Middleton","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"M. J.","family":"Marshall","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"297","published-online":{"date-parts":[[2009,3,10]]},"reference":[{"key":"9046_CR1","doi-asserted-by":"crossref","first-page":"61","DOI":"10.5507\/bp.2001.013","volume":"145","author":"D Stejskal","year":"2001","unstructured":"Stejskal D, Bartek J, Pastorkova R, Ruzicka V, Oral I, Horalik D. Osteoprotegerin, RANK, RANKL. Biomed Papers. 2001;145:61\u20134.","journal-title":"Biomed Papers"},{"key":"9046_CR2","doi-asserted-by":"publisher","first-page":"175","DOI":"10.1038\/36593","volume":"390","author":"DM Anderson","year":"1997","unstructured":"Anderson DM, Maraskovsky E, Billingsley WL, Dougall WC, Tometsko ME, Roux ER, et al. A homologue of the TNF receptor and its ligand enhance T-cell growth and dendritic-cell function. Nature. 1997;390:175\u20139.","journal-title":"Nature"},{"key":"9046_CR3","doi-asserted-by":"publisher","first-page":"145","DOI":"10.1055\/s-2001-11050","volume":"126","author":"LC Hofbauer","year":"2001","unstructured":"Hofbauer LC, Heufelder AE. Osteoprotegerin ligand and osteoprotegerin: new concepts of the pathogenesis and therapy of metabolic bone diseases. Dtsch Med Wochenschr. 2001;126:145\u201350.","journal-title":"Dtsch Med Wochenschr"},{"key":"9046_CR4","doi-asserted-by":"publisher","first-page":"2964","DOI":"10.1210\/jc.2004-1895","volume":"90","author":"BA Mosheimer","year":"2005","unstructured":"Mosheimer BA, Kaneider NC, Feistritzer C, Djanani AM, Sturn DH, Patsch JR, et al. Syndecan-1 is involved in osteoprotegerin-induced chemotaxis in human peripheral blood monocytes. J Clin Endocrinol Metab. 2005;90:2964\u201371.","journal-title":"J Clin Endocrinol Metab"},{"key":"9046_CR5","doi-asserted-by":"publisher","first-page":"315","DOI":"10.1038\/16852","volume":"397","author":"YY Kong","year":"1999","unstructured":"Kong YY, Yoshida H, Sarosi I, Tan HL, Timms E, Capparelli C, et al. OPGL is a key regulator of osteoclastogenesis, lymphocyte development and lymph-node organogenesis. Nature. 1999;397:315\u201323.","journal-title":"Nature"},{"key":"9046_CR6","doi-asserted-by":"publisher","first-page":"41","DOI":"10.1016\/S0092-8674(00)00103-3","volume":"103","author":"JE Fata","year":"2000","unstructured":"Fata JE, Kong YY, Li J, Sasaki T, Irie-Sasaki J, Moorehead RA, et al. The osteoclast differentiation factor osteoprotegerin-ligand is essential for mammary gland development. Cell. 2000;103:41\u201350.","journal-title":"Cell"},{"key":"9046_CR7","doi-asserted-by":"publisher","first-page":"1002","DOI":"10.1128\/MCB.26.3.1002-1013.2006","volume":"26","author":"NS Kim","year":"2006","unstructured":"Kim NS, Kim HJ, Koo BK, Kwon MC, Kim YW, Cho Y, et al. Receptor activator of NF-KappaB ligand regulates the proliferation of mammary epithelial cells via Id2. Mol Cell Biol. 2006;26:1002\u201313.","journal-title":"Mol Cell Biol"},{"key":"9046_CR8","doi-asserted-by":"publisher","first-page":"289","DOI":"10.1002\/cncr.21978","volume":"107","author":"G Chen","year":"2006","unstructured":"Chen G, Sirkar K, Aprikian A, Potti A, Goltzman D, Rabbani S. Expression of RANKL\/RANK\/OPG in primary and metastatic human prostate cancer as markers of disease stage and functional regulation. Cancer. 2006;107:289\u201398.","journal-title":"Cancer"},{"key":"9046_CR9","doi-asserted-by":"publisher","first-page":"195","DOI":"10.1530\/eje.0.1410195","volume":"141","author":"LC Hofbauer","year":"1999","unstructured":"Hofbauer LC. Osteoprotegerin ligand and osteoprotegerin: novel implications for osteoclast biology and bone metabolism. Eur J Endocrinol. 1999;141:195\u2013210.","journal-title":"Eur J Endocrinol"},{"key":"9046_CR10","doi-asserted-by":"publisher","first-page":"111","DOI":"10.1038\/24036","volume":"396","author":"GV Heijne","year":"1998","unstructured":"Heijne GV. Life and death of a signal peptide. Nature. 1998;396:111\u20133.","journal-title":"Nature"},{"key":"9046_CR11","unstructured":"Warren G. Sorting signals and cellular membranes. 2nd ed. 1993. pp. 166\u201372."},{"key":"9046_CR12","doi-asserted-by":"publisher","first-page":"165","DOI":"10.1016\/S0092-8674(00)81569-X","volume":"93","author":"DL Lacey","year":"1998","unstructured":"Lacey DL, Timms E, Tan HL, Kelley MJ, Dunstan CR, Burgess T, et al. Osteoprotegerin ligand is a cytokine that regulates osteoclast differentiation and activation. Cell. 1998;93:165\u201376.","journal-title":"Cell"},{"key":"9046_CR13","doi-asserted-by":"publisher","first-page":"25190","DOI":"10.1074\/jbc.272.40.25190","volume":"272","author":"BR Wong","year":"1997","unstructured":"Wong BR, Rho J, Arron J, Robinson E, Orlinick J, Chao M, et al. TRANCE Is a novel ligand of the tumor necrosis factor receptor family that activates C-Jun N-terminal kinase in T cells. J Biol Chem. 1997;272:25190\u20134.","journal-title":"J Biol Chem"},{"key":"9046_CR14","doi-asserted-by":"publisher","first-page":"109","DOI":"10.1016\/S8756-3282(99)00121-0","volume":"25","author":"H Yasuda","year":"1999","unstructured":"Yasuda H, Shima N, Nakagawa N, Yamaguchi K, Kinosaki M, Goto M, et al. A novel molecular mechanism modulating osteoclast differentiation and function. Bone. 1999;25:109\u201313.","journal-title":"Bone"},{"key":"9046_CR15","doi-asserted-by":"publisher","first-page":"490","DOI":"10.1001\/jama.292.4.490","volume":"292","author":"LC Hofbauer","year":"2004","unstructured":"Hofbauer LC, Schoppet M. Clinical implications of the osteoprotegerin\/RANKL\/RANK system for bone and vascular diseases. JAMA. 2004;292:490\u20135.","journal-title":"JAMA"},{"key":"9046_CR16","first-page":"297","volume":"53","author":"D Drugarin","year":"2003","unstructured":"Drugarin D, Drugarin M, Negru S, Cioaca R. RANKL-RANK\/OPG molecular complex-control factors in bone remodeling. Timisora Med J. 2003;53:297\u2013302.","journal-title":"Timisora Med J"},{"key":"9046_CR17","doi-asserted-by":"crossref","first-page":"1221","DOI":"10.1172\/JCI200317215","volume":"111","author":"G Eghbali-Fatourechi","year":"2003","unstructured":"Eghbali-Fatourechi G, Khosla S, Sanyal A, Boyle WJ, Lacey DL, Riggs BL. Role of RANK ligand in mediating increased bone resorption in early postmenopausal women. J Clin Invest. 2003;111:1221\u201330.","journal-title":"J Clin Invest"},{"key":"9046_CR18","doi-asserted-by":"publisher","first-page":"244","DOI":"10.1111\/j.1365-2141.2004.05024.x","volume":"126","author":"S Bord","year":"2004","unstructured":"Bord S, Frith E, Ireland DC, Scott MA, Craig JIO, Compston JE. Synthesis of osteoprotegerin and RANKL by megakaryocytes is modulated by oestrogen. Br J Haematol. 2004;126:244\u201351.","journal-title":"Br J Haematol"},{"key":"9046_CR19","doi-asserted-by":"publisher","first-page":"1419","DOI":"10.1210\/en.142.4.1419","volume":"142","author":"T Ikeda","year":"2001","unstructured":"Ikeda T, Kasai M, Utsuyama M, Hirokawa K. Determination of three isoforms of the receptor activator of nuclear factor-KB ligand and their differential expression in bone and thymus. Endocrinology. 2001;142:1419\u201326.","journal-title":"Endocrinology"},{"key":"9046_CR20","doi-asserted-by":"publisher","first-page":"802","DOI":"10.1002\/cncr.11134","volume":"97","author":"EM Sordillo","year":"2003","unstructured":"Sordillo EM, Pearse RN. RANK-Fc: a therapeutic antagonist for RANK-L in myeloma. Cancer. 2003;97:802\u201312.","journal-title":"Cancer"},{"key":"9046_CR21","doi-asserted-by":"publisher","first-page":"19","DOI":"10.1016\/S0083-6729(04)67002-6","volume":"67","author":"S Ito","year":"2004","unstructured":"Ito S, Hata T. Crystal structure of RANK ligand involved in bone metabolism. Vitam Horm. 2004;67:19\u201333.","journal-title":"Vitam Horm"},{"key":"9046_CR22","doi-asserted-by":"publisher","first-page":"41700","DOI":"10.1074\/jbc.M507000200","volume":"280","author":"A Hikita","year":"2005","unstructured":"Hikita A, Kadono Y, Chikuda H, Fukuda A, Wakeyama H, Yasuda H, et al. Identification of an alternatively spliced variant of Ca2+-promoted Ras inactivator as a possible regulator of RANKL shedding. J Biol Chem. 2005;280:41700\u20136.","journal-title":"J Biol Chem"},{"key":"9046_CR23","doi-asserted-by":"publisher","first-page":"309","DOI":"10.1016\/S0092-8674(00)80209-3","volume":"89","author":"WS Simonet","year":"1997","unstructured":"Simonet WS, Lacey DL, Dunstan CR, Kelley M, Chang MS, Luthy R, et al. Osteoprotegerin: a novel secreted protein involved in the regulation of bone density. Cell. 1997;89:309\u201319.","journal-title":"Cell"},{"key":"9046_CR24","doi-asserted-by":"crossref","first-page":"347","DOI":"10.1038\/emm.2002.49","volume":"34","author":"KM Woo","year":"2002","unstructured":"Woo KM, Choi Y, Ko S-H, Ko JS, Oh K-O, KK Kim. Osteoprotegerin is present on the membrane of osteoclasts isolated from mouse long bones. Exp Mol Med. 2002;34:347\u201352.","journal-title":"Exp Mol Med"},{"key":"9046_CR25","doi-asserted-by":"publisher","first-page":"1411","DOI":"10.1359\/JBMR.040604","volume":"19","author":"T Kondo","year":"2004","unstructured":"Kondo T, Kitazawa R, Maeda S, Kitazawa S. 1 Alpha, 25 Dihydroxyvitamin D3 rapidly regulates the mouse osteoprotegerin gene through dual pathways. J Bone Miner Res. 2004;19:1411\u20139.","journal-title":"J Bone Miner Res"},{"key":"9046_CR26","doi-asserted-by":"publisher","first-page":"5117","DOI":"10.1074\/jbc.273.9.5117","volume":"273","author":"K Yamaguchi","year":"1998","unstructured":"Yamaguchi K, Kinosaki M, Goto M, Kobayashi F, Tsuda E, Morinaga T, et al. Characterization of structural domains of human osteoclastogenesis inhibitory factor. J Biol Chem. 1998;273:5117\u201323.","journal-title":"J Biol Chem"},{"key":"9046_CR27","doi-asserted-by":"publisher","first-page":"263","DOI":"10.1139\/o03-077","volume":"82","author":"SM Dehm","year":"2004","unstructured":"Dehm SM, Bonham K. SRC gene expression in human cancer: the role of transcriptional activation. Biochem Cell Biol. 2004;82:263\u201374.","journal-title":"Biochem Cell Biol"},{"key":"9046_CR28","doi-asserted-by":"publisher","first-page":"17","DOI":"10.1016\/j.molmed.2005.11.007","volume":"12","author":"T Wada","year":"2006","unstructured":"Wada T, Nakashima T, Hiroshi N, Penninger JM. RANKL-RANK signaling in osteoclastogenesis and bone disease. TRENDS Mol Med. 2006;12:17\u201325.","journal-title":"TRENDS Mol Med"},{"key":"9046_CR29","doi-asserted-by":"publisher","first-page":"208","DOI":"10.1016\/S8756-3282(00)00431-2","volume":"28","author":"EA O\u2019Brien","year":"2001","unstructured":"O\u2019Brien EA, Williams JH, Marshall MJ. Osteoprotegerin is produced when prostaglandin synthesis is inhibited causing osteoclasts to detach from the surface of mouse parietal bone and attach to the endocranial membrane. Bone. 2001;28:208\u201314.","journal-title":"Bone"},{"key":"9046_CR30","doi-asserted-by":"publisher","first-page":"751","DOI":"10.1016\/j.devcel.2005.02.017","volume":"8","author":"DA Glass","year":"2005","unstructured":"Glass DA, Bialek P, Ahn JD, Starbuck M, Patel MS, Clevers H, et al. Canonical Wnt signaling in differentiated osteoblasts controls osteoclast differentiation. Dev Cell. 2005;8:751\u201364.","journal-title":"Dev Cell"},{"key":"9046_CR31","doi-asserted-by":"publisher","first-page":"7665","DOI":"10.1158\/0008-5472.CAN-06-4666","volume":"67","author":"N Giuliani","year":"2007","unstructured":"Giuliani N, Morandi F, Tagliaferri S, Lazzaretti M, Donofrio G, Bonomini S, et al. Production of Wnt inhibitors by myeloma cells: potential effects on canonical Wnt pathway in the bone microenvironment. Cancer Res. 2007;67:7665\u201374.","journal-title":"Cancer Res"},{"key":"9046_CR32","doi-asserted-by":"publisher","first-page":"R100","DOI":"10.1186\/ar2301","volume":"9","author":"B Hopwood","year":"2007","unstructured":"Hopwood B, Tsykin A, Findlay DM, Fazzalari NL. Microarray gene expression profiling of osteoarthritic bone suggests altered bone remodelling, WNT and transforming growth factor-beta\/bone morphogenic protein signalling. Arthritis Res Ther. 2007;9:R100.","journal-title":"Arthritis Res Ther"},{"key":"9046_CR33","doi-asserted-by":"publisher","first-page":"1873","DOI":"10.1359\/JBMR.040807","volume":"19","author":"KD Hausler","year":"2004","unstructured":"Hausler KD, Horwood NJ, Chuman Y, Fisher JL, Ellis J, Martin TJ, et al. Secreted frizzled-related protein-1 inhibits RANKL-dependent osteoclast formation. J Bone Miner Res. 2004;19:1873\u201381.","journal-title":"J Bone Miner Res"},{"key":"9046_CR34","doi-asserted-by":"publisher","first-page":"495","DOI":"10.1016\/S0167-5699(00)01718-7","volume":"21","author":"YY Kong","year":"2000","unstructured":"Kong YY, Boyle WJ, Penninger JM. Osteoprotegerin ligand: a regulator of immune responses and bone physiology. Immunol Today. 2000;21:495\u2013502.","journal-title":"Immunol Today"},{"key":"9046_CR35","doi-asserted-by":"publisher","first-page":"14363","DOI":"10.1074\/jbc.273.23.14363","volume":"273","author":"JG Emery","year":"1998","unstructured":"Emery JG, McDonnell P, Burke MB, Deen KC, Lyn S, Silverman C, et al. Osteoprotegerin is a receptor for the cytotoxic ligand TRAIL. J Biol Chem. 1998;273:14363\u20137.","journal-title":"J Biol Chem"},{"key":"9046_CR36","doi-asserted-by":"crossref","first-page":"971","DOI":"10.1172\/JCI13890","volume":"108","author":"J Lam","year":"2001","unstructured":"Lam J, Nelson CA, Ross FP, Teitelbaum SL, Fremont DH. Crystal structure of the TRANCE\/RANKL cytokine reveals determinants of receptor-ligand specificity. J Clin Invest. 2001;108:971\u20139.","journal-title":"J Clin Invest"},{"key":"9046_CR37","doi-asserted-by":"crossref","first-page":"1045","DOI":"10.1152\/ajplung.2000.278.5.L1045","volume":"278","author":"BR Gochuico","year":"2000","unstructured":"Gochuico BR, Zhang J, Ma BY, Marshak-Rothstein A, Fine A. TRAIL expression in vascular smooth muscle. Am J Physiol Lung Cell Mol Physiol. 2000;278:1045\u201351.","journal-title":"Am J Physiol Lung Cell Mol Physiol"},{"key":"9046_CR38","doi-asserted-by":"publisher","first-page":"514","DOI":"10.1002\/jemt.10375","volume":"61","author":"MH Helfrich","year":"2003","unstructured":"Helfrich MH. Osteoclast diseases. Microsc Res Tech. 2003;61:514\u201332.","journal-title":"Microsc Res Tech"},{"key":"9046_CR39","doi-asserted-by":"publisher","first-page":"45","DOI":"10.1038\/71667","volume":"24","author":"AE Hughes","year":"2000","unstructured":"Hughes AE, Ralson SH, Marken J, Bell J, MaCPherson H, Wallace RGH, et al. Mutations in the TNFRSF11A, affecting the signal peptide of RANK, cause familial expansile osteolysis. Nat Genet. 2000;24:45\u20138.","journal-title":"Nat Genet"},{"key":"9046_CR40","doi-asserted-by":"publisher","first-page":"143","DOI":"10.1196\/annals.1346.016","volume":"1068","author":"MP Whyte","year":"2006","unstructured":"Whyte MP. Paget\u2019s Disease of bone and genetic disorders of RANKL\/OPG\/RANK\/NF-KappaB signalling. Ann N Y Acad Sci. 2006;1068:143\u201364.","journal-title":"Ann N Y Acad Sci"},{"key":"9046_CR41","doi-asserted-by":"publisher","first-page":"1698","DOI":"10.1359\/jbmr.080511","volume":"23","author":"MP Whyte","year":"2008","unstructured":"Whyte MP, McAlister WH, Novack DV, Clements KL, Schoenecker PL, Wenkert D. Bisphosphonate-induced osteopetrosis: novel bone modeling defects, metaphyseal osteopenia, and osteosclerosis fractures after drug exposure ceases. J Bone Miner Res. 2008;23:1698\u2013707.","journal-title":"J Bone Miner Res"},{"key":"9046_CR42","doi-asserted-by":"publisher","first-page":"26","DOI":"10.1359\/jbmr.2002.17.1.26","volume":"17","author":"MP Whyte","year":"2002","unstructured":"Whyte MP, Huhges AE. Expansile skeletal hyperphosphatasia is caused by a 15-base pair tandem duplication in TNFRSF11A encoding RANK and is allelic to familial expansile osteolysis. J Bone Miner Res. 2002;17:26\u20139.","journal-title":"J Bone Miner Res"},{"key":"9046_CR43","doi-asserted-by":"publisher","first-page":"960","DOI":"10.1038\/ng2076","volume":"39","author":"C Sobacchi","year":"2007","unstructured":"Sobacchi C, Frattini A, Guerrini MM, Abinun M, Pangrazio A, Susani L, et al. Osteoclast-poor human osteopetrosis due to mutations in the gene encoding RANKL. Nat Genet. 2007;39:960\u20132.","journal-title":"Nat Genet"},{"key":"9046_CR44","doi-asserted-by":"publisher","first-page":"2119","DOI":"10.1093\/hmg\/11.18.2119","volume":"11","author":"T Cundy","year":"2002","unstructured":"Cundy T, Hegde M, Naot D, Chong B, King A, Wallace R, et al. A mutation in the gene TNFRSF11B encoding osteoprotegerin causes an idiopathic hyperphosphatasia phenotype. Hum Mol Genet. 2002;11:2119\u201327.","journal-title":"Hum Mol Genet"},{"key":"9046_CR45","doi-asserted-by":"publisher","first-page":"175","DOI":"10.1056\/NEJMoa013096","volume":"347","author":"MP Whyte","year":"2002","unstructured":"Whyte MP, Obrecht SE, Finnegan PM, Jones JL, Podgornik MN, McAlister WH, et al. Osteoprotegerin deficiency and Juvenile Paget\u2019s Disease. N Engl J Med. 2002;347:175\u201384.","journal-title":"N Engl J Med"},{"key":"9046_CR46","doi-asserted-by":"publisher","first-page":"337","DOI":"10.1038\/nature01658","volume":"423","author":"WJ Boyle","year":"2003","unstructured":"Boyle WJ, Simonet WS, Lacey DL. Osteoclast differentiation and activation. Nature. 2003;423:337\u201342.","journal-title":"Nature"},{"issue":"suppl 1","key":"9046_CR47","first-page":"S139","volume":"17","author":"B Chong","year":"2002","unstructured":"Chong B, Hegde M, Fawkner M, Seidel J, Tuysuz B, Yuksel B, et al. Mutations in the gene encoding osteoprotegerin cause idiopathic hyperphosphatasia. J Bone Miner Res. 2002;17(suppl 1):S139.","journal-title":"J Bone Miner Res"},{"key":"9046_CR48","doi-asserted-by":"publisher","first-page":"2095","DOI":"10.1359\/jbmr.2003.18.12.2095","volume":"18","author":"B Chong","year":"2003","unstructured":"Chong B, Hegde M, Fawkner M, Simonet S, Cassinelli H, Coker M, et al. Idiopathic hyperphosphatasia and TNFRSF11B mutations: relationships between phenotype and genotype. J Bone Miner Res. 2003;18:2095\u2013104.","journal-title":"J Bone Miner Res"},{"key":"9046_CR49","doi-asserted-by":"publisher","first-page":"4821","DOI":"10.1200\/JCO.2005.02.911","volume":"23","author":"GD Roodman","year":"2005","unstructured":"Roodman GD. High bone turnover markers predict poor outcome in patients with bone metastasis. J Clin Oncol. 2005;23:4821\u20132.","journal-title":"J Clin Oncol"},{"key":"9046_CR50","doi-asserted-by":"publisher","first-page":"221","DOI":"10.1080\/02841860600635870","volume":"46","author":"G Mountzios","year":"2007","unstructured":"Mountzios G, Dimopoulos MA, Bamias A, Papadopoulos G, Kastritis E, Syrigos K, et al. Abnormal bone remodeling process is due to an imbalance in the receptor activator of nuclear factor-kappaB ligand (RANKL)\/osteoprotegerin (OPG) axis in patients with solid tumors metastatic to the skeleton. Acta Oncol. 2007;46:221\u20139.","journal-title":"Acta Oncol"},{"key":"9046_CR51","doi-asserted-by":"publisher","first-page":"169","DOI":"10.1007\/s10911-005-5399-8","volume":"10","author":"W Kozlow","year":"2005","unstructured":"Kozlow W, Guise TA. Breast cancer metastasis to bone: mechanisms of osteolysis and implications for therapy. J Mammary Gland Biol Neoplasia. 2005;10:169\u201380.","journal-title":"J Mammary Gland Biol Neoplasia"},{"key":"9046_CR52","doi-asserted-by":"crossref","unstructured":"Klein A, Olendrowitz C, Schmutzler R, Hampl J, Schlag PM, Maass N, Arnold N, Wessel R, Ramser J, Meindl A, Scherneck S, Seitz S. Identification of brain- and bone-specific breast cancer metastasis genes. Cancer Lett. 2008. [Epub ahead of print].","DOI":"10.1016\/j.canlet.2008.11.017"},{"key":"9046_CR53","doi-asserted-by":"publisher","first-page":"584","DOI":"10.1038\/nrc867","volume":"2","author":"GR Mundy","year":"2002","unstructured":"Mundy GR. Metastasis to bone: causes, consequences and therapeutic opportunities. Nat Rev Cancer. 2002;2:584\u201393.","journal-title":"Nat Rev Cancer"},{"key":"9046_CR54","doi-asserted-by":"publisher","first-page":"1710","DOI":"10.1158\/0008-5472.CAN-04-2033","volume":"65","author":"E Corey","year":"2005","unstructured":"Corey E, Brown LG, Kiefer JA, Quinn JE, Pitts TE, Blair JM, et al. Osteoprotegerin in prostate cancer bone metastasis. Cancer Res. 2005;65:1710\u20138.","journal-title":"Cancer Res"},{"key":"9046_CR55","doi-asserted-by":"publisher","first-page":"91","DOI":"10.1358\/dot.2002.38.2.820105","volume":"38","author":"ET Keller","year":"2002","unstructured":"Keller ET. The role of osteoclastic activity in prostate cancer skeletal metastases. Drugs Today (Barc). 2002;38:91\u2013102.","journal-title":"Drugs Today (Barc)"},{"key":"9046_CR56","first-page":"204","volume":"7","author":"I Yoshino","year":"2001","unstructured":"Yoshino I, Yohena T, Kitajima M, Ushijima C, Nishioka K, Ichinose Y, et al. Survival of non-small cell lung cancer patients with postoperative recurrence at distant organs. Ann Thorac Cardiovasc Surg. 2001;7:204\u20139.","journal-title":"Ann Thorac Cardiovasc Surg"},{"key":"9046_CR57","doi-asserted-by":"publisher","first-page":"1571","DOI":"10.1359\/jbmr.060706","volume":"21","author":"BT Feeley","year":"2006","unstructured":"Feeley BT, Liu NQ, Conduah AH, Krenek L, Roth K, Dougall WC, et al. Mixed metastatic lung cancer lesions in bone are inhibited by noggin overexpression and Rank:Fc administration. J Bone Miner Res. 2006;21:1571\u201380.","journal-title":"J Bone Miner Res"},{"key":"9046_CR58","doi-asserted-by":"publisher","first-page":"9","DOI":"10.1007\/s10585-006-9006-1","volume":"23","author":"ES Nakamura","year":"2006","unstructured":"Nakamura ES, Koizumi K, Kobayashi M, Saitoh Y, Arita Y, Nakayama T, et al. RANKL-induced CCL22\/macrophage-derived chemokine produced from osteoclasts potentially promotes the bone metastasis of lung cancer expressing its receptor CCR4. Clin Exp Metastasis. 2006;23:9\u201318.","journal-title":"Clin Exp Metastasis"},{"key":"9046_CR59","doi-asserted-by":"publisher","first-page":"3527","DOI":"10.1182\/blood.V98.13.3527","volume":"98","author":"N Giuliani","year":"2001","unstructured":"Giuliani N, Bataille R, Mancini C, Lazzaretti M, Barill\u00e9 S. Myeloma cells induce imbalance in the osteoprotegerin\/osteoprotegerin ligand system in the human bone marrow environment. Blood. 2001;98:3527\u201333.","journal-title":"Blood"},{"key":"9046_CR60","doi-asserted-by":"publisher","first-page":"2412","DOI":"10.1101\/gad.13.18.2412","volume":"13","author":"WC Dougall","year":"1999","unstructured":"Dougall WC, Glaccum M, Charrier K, Kathy R, Brasel K, Smedt T, et al. RANK is essential for osteoclast and lymph node development. Genes Dev. 1999;13:2412\u201324.","journal-title":"Genes Dev"},{"key":"9046_CR61","doi-asserted-by":"publisher","first-page":"1260","DOI":"10.1101\/gad.12.9.1260","volume":"12","author":"N Bucay","year":"1998","unstructured":"Bucay N, Sarosi I, Dunstan CR, Morony S, Tarpley J, Capparelli C, et al. Osteoprotegerin-deficient mice develop early onset osteoporosis and arterial calcification. Genes Dev. 1998;12:1260\u20138.","journal-title":"Genes Dev"},{"key":"9046_CR62","doi-asserted-by":"publisher","first-page":"503","DOI":"10.1093\/jmicro\/52.6.503","volume":"52","author":"N Amizuka","year":"2003","unstructured":"Amizuka N, Shimomura J, Li M, Seki Y, Oda K, Henderson JE, et al. Defective bone remodelling in osteoprotegerin-deficient mice. J Electron Microsc. 2003;52:503\u201313.","journal-title":"J Electron Microsc"},{"key":"9046_CR63","doi-asserted-by":"publisher","first-page":"821","DOI":"10.1056\/NEJMoa044459","volume":"354","author":"MR McClung","year":"2006","unstructured":"McClung MR, Lewiecki EM, Cohen SB, Bolognese MA, Woodson GC, Moffett AH, et al. Denosumab in postmenopausal women with low bone mineral density. N Engl J Med. 2006;354:821\u201331.","journal-title":"N Engl J Med"},{"key":"9046_CR64","doi-asserted-by":"publisher","first-page":"153","DOI":"10.1359\/jbmr.0809010","volume":"24","author":"JP Brown","year":"2008","unstructured":"Brown JP, Prince RL, Deal C, Recker RR, Kiel DP, de Gregorio LH, et al. Comparison of the effect of denosumab and alendronate on bone mineral density and biochemical markers of bone turnover in postmenopausal women with low bone mass: a randomized, blinded, phase 3 trial. J Bone Miner Res. 2008;24:153\u201361.","journal-title":"J Bone Miner Res"},{"key":"9046_CR65","doi-asserted-by":"publisher","first-page":"4431","DOI":"10.1200\/JCO.2007.11.8604","volume":"25","author":"A Lipton","year":"2007","unstructured":"Lipton A, Steger GG, Figueroa J, Alvarado C, Solal-Celigny P, Body JJ, et al. Randomized active-controlled phase II study of denosumab efficacy and safety in patients with breast cancer-related bone metastases. J Clin Oncol. 2007;25:4431\u20137.","journal-title":"J Clin Oncol"},{"key":"9046_CR66","doi-asserted-by":"publisher","first-page":"1299","DOI":"10.1002\/art.23417","volume":"58","author":"SB Cohen","year":"2008","unstructured":"Cohen SB, Dore RK, Lane NE, Ory PA, Peterfy CG, Sharp JT, et al. Denosumab treatment effects on structural damage, bone mineral density, and bone turnover in rheumatoid arthritis: a twelve-month, multicenter, randomized, double-blind, placebo-controlled, phase II clinical trial. Arthritis Rheum. 2008;58:1299\u2013309.","journal-title":"Arthritis Rheum"},{"key":"9046_CR67","doi-asserted-by":"publisher","first-page":"555","DOI":"10.1124\/jpet.108.137703","volume":"326","author":"A Marathe","year":"2008","unstructured":"Marathe A, Peterson MC, Mager DE. Integrated cellular bone homeostasis model for denosumab pharmacodynamics in multiple myeloma patients. J Pharmacol Exp Ther. 2008;326:555\u201362.","journal-title":"J Pharmacol Exp Ther"},{"key":"9046_CR68","doi-asserted-by":"publisher","first-page":"887","DOI":"10.1002\/cncr.11138","volume":"97","author":"JJ Body","year":"2003","unstructured":"Body JJ, Greipp P, Coleman RE, Facon T, Geurs F, Fermand JP, et al. A phase I study of AMGN-0007, a recombinant osteoprotegerin construct, in patients with multiple myeloma or breast carcinoma related bone metastases. Cancer. 2003;97:887\u201392.","journal-title":"Cancer"},{"key":"9046_CR69","doi-asserted-by":"publisher","first-page":"871","DOI":"10.1038\/mt.2008.48","volume":"16","author":"D Chanda","year":"2008","unstructured":"Chanda D, Isayeva T, Kumar S, Siegal GP, Szafran AA, Zinn KR, et al. Systemic osteoprotegerin gene therapy restores tumor-induced bone loss in a therapeutic model of breast cancer bone metastasis. Mol Ther. 2008;16:871\u20138.","journal-title":"Mol Ther"},{"key":"9046_CR70","doi-asserted-by":"publisher","first-page":"143","DOI":"10.3816\/SCT.2006.n.012","volume":"3","author":"L Costa","year":"2006","unstructured":"Costa L, Lipton A, Coleman RE. Role of bisphosphonates for the management of skeletal complications and bone pain from skeletal metastases. Support Cancer Ther. 2006;3:143\u201353.","journal-title":"Support Cancer Ther"}],"container-title":["Current Reviews in Musculoskeletal Medicine"],"original-title":[],"language":"en","link":[{"URL":"http:\/\/link.springer.com\/content\/pdf\/10.1007\/s12178-009-9046-7.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"http:\/\/link.springer.com\/article\/10.1007\/s12178-009-9046-7\/fulltext.html","content-type":"text\/html","content-version":"vor","intended-application":"text-mining"},{"URL":"http:\/\/www.springerlink.com\/index\/pdf\/10.1007\/s12178-009-9046-7","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"},{"URL":"http:\/\/link.springer.com\/content\/pdf\/10.1007\/s12178-009-9046-7.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2019,5,18]],"date-time":"2019-05-18T14:29:49Z","timestamp":1558189789000},"score":1,"resource":{"primary":{"URL":"http:\/\/link.springer.com\/10.1007\/s12178-009-9046-7"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2009,3]]},"references-count":70,"journal-issue":{"issue":"1","published-print":{"date-parts":[[2009,3]]}},"alternative-id":["9046"],"URL":"https:\/\/doi.org\/10.1007\/s12178-009-9046-7","relation":{},"ISSN":["1935-973X","1935-9748"],"issn-type":[{"value":"1935-973X","type":"print"},{"value":"1935-9748","type":"electronic"}],"subject":[],"published":{"date-parts":[[2009,3]]}}}